Drug interactions
Bosentan + Empagliflozin-linagliptin
Severity: Minor
Bosentan and Empagliflozin-linagliptin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Bosentan induces CYP3A4 and may modestly reduce linagliptin exposure, possibly weakening its glucose-lowering effect. The clinical impact is expected to be limited.
What this interaction means in plain words
Bosentan and Empagliflozin-linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bosentan belongs to Miscellaneous; Empagliflozin-linagliptin belongs to Endocrine.
Why it happens
CYP3A4 induction by bosentan increases the metabolic clearance of linagliptin.
What to do
Monitor glucose and HbA1c after starting or stopping bosentan, and adjust antidiabetic therapy if control worsens.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Empagliflozin-linagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Frequently asked questions
Can I take Bosentan with Empagliflozin-linagliptin?
MediHelp rates the interaction as minor. Bosentan and Empagliflozin-linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Bosentan induces CYP3A4 and may modestly reduce linagliptin exposure, possibly weakening its glucose-lowering effect. The clinical impact is expected to be limited.
How serious is the interaction between Bosentan and Empagliflozin-linagliptin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glucose and HbA1c after starting or stopping bosentan, and adjust antidiabetic therapy if control worsens.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
